Univariate analysis of demographic risk factors for clinical extensive chronic graft-versus-host disease
| Factor . | No. patients . | Chronic GVHD HR (95% CI)* . | P . |
|---|---|---|---|
| Patient age | |||
| Younger than 38 years | 55 | 1.0 | |
| 38 years or older | 61 | 1.4 (0.8-2.2) | .2 |
| Patient sex | |||
| Male | 58 | 1.0 | |
| Female | 58 | 0.9 (0.6-1.5) | .8 |
| Diagnosis | |||
| Leukemia/myelodysplastic syndrome | 66 | 1.0 | |
| Lymphoma/Hodgkin disease/myeloma | 42 | 1.0 (0.6-1.6) | .9 |
| Solid tumor | 8 | 0.9 (0.3-3.0) | .9 |
| Disease status | |||
| First remission or chronic phase | 12 | 1.0 | |
| Second remission or accelerated phase | 31 | 1.4 (0.5-3.7) | .5 |
| Relapse or blast crisis | 73 | 1.4 (0.6-3.6) | .5 |
| Preparative regimen | |||
| Total body irradiation–based | 30 | 1.0 | |
| Chemotherapy alone | 86 | 0.97 (0.6-1.7) | .9 |
| GVHD prophylaxis | |||
| Cyclosporine/methylprednisolone | 32 | 1.0 | |
| Tacrolimus/methylprednisolone | 45 | 0.8 (0.5-1.5) | .6 |
| Tacrolimus/methotrexate | 39 | 0.3 (0.2-0.6) | < .001 |
| Grades 2-4 acute GVHD | |||
| No | 83 | 1.0 | |
| Yes | 33 | 1.9 (1.1-3.1) | .013 |
| On steroids at day 100 | |||
| No | 70 | 1.0 | |
| Yes | 46 | 1.7 (1.1-2.8) | .027 |
| Cytomegalovirus serology before transplant | |||
| Patient and donor seronegative | 12 | 1.0 | |
| Patient or donor seropositive | 104 | 0.5 (0.2-1.1) | .07 |
| Factor . | No. patients . | Chronic GVHD HR (95% CI)* . | P . |
|---|---|---|---|
| Patient age | |||
| Younger than 38 years | 55 | 1.0 | |
| 38 years or older | 61 | 1.4 (0.8-2.2) | .2 |
| Patient sex | |||
| Male | 58 | 1.0 | |
| Female | 58 | 0.9 (0.6-1.5) | .8 |
| Diagnosis | |||
| Leukemia/myelodysplastic syndrome | 66 | 1.0 | |
| Lymphoma/Hodgkin disease/myeloma | 42 | 1.0 (0.6-1.6) | .9 |
| Solid tumor | 8 | 0.9 (0.3-3.0) | .9 |
| Disease status | |||
| First remission or chronic phase | 12 | 1.0 | |
| Second remission or accelerated phase | 31 | 1.4 (0.5-3.7) | .5 |
| Relapse or blast crisis | 73 | 1.4 (0.6-3.6) | .5 |
| Preparative regimen | |||
| Total body irradiation–based | 30 | 1.0 | |
| Chemotherapy alone | 86 | 0.97 (0.6-1.7) | .9 |
| GVHD prophylaxis | |||
| Cyclosporine/methylprednisolone | 32 | 1.0 | |
| Tacrolimus/methylprednisolone | 45 | 0.8 (0.5-1.5) | .6 |
| Tacrolimus/methotrexate | 39 | 0.3 (0.2-0.6) | < .001 |
| Grades 2-4 acute GVHD | |||
| No | 83 | 1.0 | |
| Yes | 33 | 1.9 (1.1-3.1) | .013 |
| On steroids at day 100 | |||
| No | 70 | 1.0 | |
| Yes | 46 | 1.7 (1.1-2.8) | .027 |
| Cytomegalovirus serology before transplant | |||
| Patient and donor seronegative | 12 | 1.0 | |
| Patient or donor seropositive | 104 | 0.5 (0.2-1.1) | .07 |
Hazard ratio (95% CI) at 18 months in comparison with the reference group with a hazard ratio of 1.0.